Patient characteristics
| Patient (PIN) . | Age/sex . | Main “high-risk” feature at diagnosis . | Additional risk feature(s) at diagnosis . | ISS stage at diagnosis . | R-ISS stage at diagnosis . | Number of regimens before autoHCT* . | Days from autoHCT to alloHCT . | Donor type . | HCT-CI . | Bortezomib initiated . | Bortezomib completed . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 39/M | ISS III | — | III | II | 3 | NA | NA | 2 | NA | NA |
| 2 | 63/M | t(14;20) | Δ 13 by cyto | I | I | 3 | 61 | MUD | 2 | Y | Y |
| 3 | 42/M | del 17p, t(4;14) | 1q+, Δ 13 by cyto | III | III | 1 | 48 | MRD | 3 | Y | Y |
| 4 | 48/F | del 17p | — | III | III | 2 | 87 | MUD | 4 | N | NA |
| 5 | 47/M | del 17p | — | II | II | 3 | 106 | MRD | 1 | Y | N |
| 6 | 47/M | del 17p | — | I | II | 4 | 53 | MRD | 2 | Y | N |
| 7 | 48/F | del 17p, t(4;14) | — | III | III | 3 | 65 | MRD | 2 | Y | Y |
| 8 | 41/F | ISS III | — | III | II | 2 | 58 | MRD | 2 | Y | N |
| 9 | 46/F | ISS III | Δ 13 by cyto | III | III | 2 | 57 | MUD | 3 | Y | N |
| 10 | 44/M | del 17p, t(4;14) | — | III | III | 1 | 60 | MRD | 2 | Y | Y |
| 11 | 59/F | del 17p | — | I | II | 1 | 168 | MRD | 3 | Y | Y |
| 12 | 52/F | ISS III | Δ 13 by cyto | III | III | 2 | 76 | MRD | 1 | Y | N |
| 13 | 56/F | ISS III | Complex karyotype | III | II | 2 | 56 | MUD | 5 | N | NA |
| 14 | 52/M | del 17p | — | III | III | 3 | 111 | MRD | 2 | N | NA |
| 15 | 69/M | t(4;14), ISS III | — | III | III | 1 | 101 | MUD | 3 | N | NA |
| 16 | 62/M | t(14;16) | — | III | III | 2 | 61 | MRD | 0 | Y | Y |
| 17 | 46/M | t(4;14) | — | I | II | 3 | 59 | MUD | 2 | Y | N |
| 18 | 43/F | del 17p | Δ 13 by cyto | III | III | 4 | 107 | MRD | 5 | Y | Y |
| 19 | 32/F | del 17p | Δ 13 by cyto | III | III | 2 | 51 | MRD | 2 | Y | Y |
| 20 | 63/M | del 17p | — | III | III | 2 | 58 | MRD | 3 | Y | N |
| 21 | 46/F | t(14;16) | — | II | II | 4 | 58 | MRD | 1 | Y | Y |
| 22 | 49/F | ISS III | — | III | III | 5 | NA | NA | 3 | N | NA |
| 23 | 63/M | del 17p, t(4;14) | — | III | III | 1 | NA | NA | 5 | N | NA |
| 24 | 57/F | ISS III | — | III | II | 2 | NA | NA | 5 | N | NA |
| 25 | 68/M | Failed prior autoHCT | Δ 13 by cyto | I | I | 6 | NA | NA | 5 | N | NA |
| 26 | 50/F | Failed 2 lines of therapy | Δ 13 by cyto | II | II | 4 | 47 | MRD | 1 | Y | Y |
| 27 | 55/M | Failed prior autoHCT, del 17p | — | III | III | 2 | 66 | MRD | 1 | Y | N |
| 28 | 62/M | Failed prior autoHCT, t(4;14) | Δ 13 by cyto | III | III | 6 | 121 | MUD | 5 | N | NA |
| 29 | 55/M | Failed prior autoHCT, del 17p | — | III | III | 3 | 108 | MUD | 5 | Y | N |
| 30 | 57/F | Failed prior autoHCT | Δ 13 by cyto | III | II | 4 | 59 | MUD | 0 | Y | N |
| 31 | 43/M | Failed prior autoHCT, del 17p | — | II | II | 5 | 41 | MRD | 2 | Y | N |
| Patient (PIN) . | Age/sex . | Main “high-risk” feature at diagnosis . | Additional risk feature(s) at diagnosis . | ISS stage at diagnosis . | R-ISS stage at diagnosis . | Number of regimens before autoHCT* . | Days from autoHCT to alloHCT . | Donor type . | HCT-CI . | Bortezomib initiated . | Bortezomib completed . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 39/M | ISS III | — | III | II | 3 | NA | NA | 2 | NA | NA |
| 2 | 63/M | t(14;20) | Δ 13 by cyto | I | I | 3 | 61 | MUD | 2 | Y | Y |
| 3 | 42/M | del 17p, t(4;14) | 1q+, Δ 13 by cyto | III | III | 1 | 48 | MRD | 3 | Y | Y |
| 4 | 48/F | del 17p | — | III | III | 2 | 87 | MUD | 4 | N | NA |
| 5 | 47/M | del 17p | — | II | II | 3 | 106 | MRD | 1 | Y | N |
| 6 | 47/M | del 17p | — | I | II | 4 | 53 | MRD | 2 | Y | N |
| 7 | 48/F | del 17p, t(4;14) | — | III | III | 3 | 65 | MRD | 2 | Y | Y |
| 8 | 41/F | ISS III | — | III | II | 2 | 58 | MRD | 2 | Y | N |
| 9 | 46/F | ISS III | Δ 13 by cyto | III | III | 2 | 57 | MUD | 3 | Y | N |
| 10 | 44/M | del 17p, t(4;14) | — | III | III | 1 | 60 | MRD | 2 | Y | Y |
| 11 | 59/F | del 17p | — | I | II | 1 | 168 | MRD | 3 | Y | Y |
| 12 | 52/F | ISS III | Δ 13 by cyto | III | III | 2 | 76 | MRD | 1 | Y | N |
| 13 | 56/F | ISS III | Complex karyotype | III | II | 2 | 56 | MUD | 5 | N | NA |
| 14 | 52/M | del 17p | — | III | III | 3 | 111 | MRD | 2 | N | NA |
| 15 | 69/M | t(4;14), ISS III | — | III | III | 1 | 101 | MUD | 3 | N | NA |
| 16 | 62/M | t(14;16) | — | III | III | 2 | 61 | MRD | 0 | Y | Y |
| 17 | 46/M | t(4;14) | — | I | II | 3 | 59 | MUD | 2 | Y | N |
| 18 | 43/F | del 17p | Δ 13 by cyto | III | III | 4 | 107 | MRD | 5 | Y | Y |
| 19 | 32/F | del 17p | Δ 13 by cyto | III | III | 2 | 51 | MRD | 2 | Y | Y |
| 20 | 63/M | del 17p | — | III | III | 2 | 58 | MRD | 3 | Y | N |
| 21 | 46/F | t(14;16) | — | II | II | 4 | 58 | MRD | 1 | Y | Y |
| 22 | 49/F | ISS III | — | III | III | 5 | NA | NA | 3 | N | NA |
| 23 | 63/M | del 17p, t(4;14) | — | III | III | 1 | NA | NA | 5 | N | NA |
| 24 | 57/F | ISS III | — | III | II | 2 | NA | NA | 5 | N | NA |
| 25 | 68/M | Failed prior autoHCT | Δ 13 by cyto | I | I | 6 | NA | NA | 5 | N | NA |
| 26 | 50/F | Failed 2 lines of therapy | Δ 13 by cyto | II | II | 4 | 47 | MRD | 1 | Y | Y |
| 27 | 55/M | Failed prior autoHCT, del 17p | — | III | III | 2 | 66 | MRD | 1 | Y | N |
| 28 | 62/M | Failed prior autoHCT, t(4;14) | Δ 13 by cyto | III | III | 6 | 121 | MUD | 5 | N | NA |
| 29 | 55/M | Failed prior autoHCT, del 17p | — | III | III | 3 | 108 | MUD | 5 | Y | N |
| 30 | 57/F | Failed prior autoHCT | Δ 13 by cyto | III | II | 4 | 59 | MUD | 0 | Y | N |
| 31 | 43/M | Failed prior autoHCT, del 17p | — | II | II | 5 | 41 | MRD | 2 | Y | N |
Patients 1-24 were newly diagnosed and eligible for the study because of high-risk features as outlined in “Methods.” Patients 25-31 had failed prior autoHCT or >2 lines of therapy and were therefore eligible for the study.
—, additional risk features were not present; Δ 13 by cyto, deletion chromosome 13 by conventional metaphase cytogenetic analysis; F, female; HCT-CI, hematopoietic cell transplant comorbidity index; M, male; PIN, patient identification number.
A change of “regimen” was defined as the addition of at least 1 new, previously not used drug for systemic myeloma-directed therapy (radiation therapy was also considered a “regimen”). Thirty-one of 31 patients (100%) received bortezomib prior to enrollment, and 25/31 patients (80%) received an immunomodulatory agent (either lenalidomide or thalidomide) before autoHCT. Sixteen patients received chemomobilization therapy, and 10 patients received external-beam radiation therapy, each counted as a separate regimen.